Search | Clinical Trials Finder

Conditions: Pulmonary Disease, Chronic Obstructive, Major Depression
Interventions: Treatment Adherence Intervention, Enhanced Care; Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 50 Years to 95 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 3
States / cities: West Haverstraw, New York • White Plains, New York

Conditions: Major Depressive Disorder
Interventions: paroxetine CR; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 646 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 71
States / cities: Birmingham, Alabama • Fairfield, Alabama • Mobile, Alabama + 63 more

Conditions: Diabetes, Depression
Interventions: Beating the Blues, Escitalopram, Placebo; Behavioral · Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 81 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Depression, End Stage Renal Disease
Interventions: Engagement Interview, Cognitive Behavioral Therapy, Antidepressant Drug Therapy; Behavioral · Drug
Lead sponsor: University of Washington; Other
Eligibility: 21 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 3
States / cities: Albuquerque, New Mexico • Dallas, Texas • Seattle, Washington

Conditions: Posttraumatic Stress Disorder, Major Depressive Disorder
Interventions: LDAEP, Placebo, sertraline; Diagnostic Test · Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: Boston, Massachusetts • Charleston, South Carolina

Conditions: Depressive Disorder, Major
Interventions: Seltorexant, Placebo, Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 752 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 84
States / cities: Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 65 more

Conditions: Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Cardiovascular Diseases, Heart Diseases, Coronary Artery Disease, Stroke
Interventions: Beating the Blues (BtB), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Usual Care; Behavioral · Drug · Other
Lead sponsor: Indiana University; Other
Eligibility: 50 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Depression
Interventions: S-adenosyl-l-methionine, Escitalopram, Placebo; Drug
Lead sponsor: Maurizio Fava, MD; Other
Eligibility: 18 Years to 80 Years
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 2
States / cities: Boston, Massachusetts • Providence, Rhode Island

Conditions: Depressive Disorder, Major
Interventions: 5 mg BI 1569912, 20 mg BI 1569912, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 10
States / cities: Garden Grove, California • Torrance, California • Miami, Florida + 7 more

Conditions: Patient Diagnosed With OCD and Resistant to SSRI Treatment, Failed SSRI Over 12 Weeks at Appropriate Doses
Interventions: AFQ056, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: San Diego, California • Watertown, Massachusetts • Brooklyn, New York

Conditions: Sexual Dysfunction
Interventions: Exercise; Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years and older · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Posttraumatic Stress Disorder
Interventions: Mirtazapine, Sertraline, Sugar pill; Drug · Other
Lead sponsor: Research Foundation for Mental Hygiene, Inc.; Other
Eligibility: 18 Years to 75 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Dysthymic Disorder
Interventions: Lexapro (escitalopram); Drug
Lead sponsor: St. Luke's-Roosevelt Hospital Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Neurological Disorder
Interventions: Psychosocial Skills-Based Intervention; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Depressive Disorder, Major
Interventions: LY2216684, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 24
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Carson, California + 21 more

Conditions: Depressive Disorder, Major, Anhedonia
Interventions: Aticaprant, Placebo; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 444 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 51
States / cities: Birmingham, Alabama • Lafayette, California • Orange, California + 40 more

Conditions: Major Depressive Disorder, Major Depressive Disorder, Recurrent, Major Depressive Disorder, Remitted
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 13 Years to 21 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hot Flashes
Interventions: Fezolinetant, Paroxetine, Citalopram, Escitalopram, Desvenlafaxine, Venlafaxine, Gabapentin, Clonidine, Pregabalin, Oxybutynin, Any other SSRI/SNRI not already specified, Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category above; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 999 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 48
States / cities: Birmingham, Alabama • Phoenix, Arizona • Lomita, California + 39 more

Conditions: Depression
Interventions: Fluoxetine 20 MG, Duloxetine 30 MG, Observation; Drug · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Adolescent Depression
Interventions: Fluoxetine, Interpersonal Psychotherapy; Drug · Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 12 Years to 18 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Major Depressive Disorder
Interventions: LY2216684, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: St Louis, Missouri • Austin, Texas

Conditions: Depression
Interventions: Citalopram, St. John's Wort, Placebos; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 3
States / cities: Los Angeles, California • Boston, Massachusetts • Pittsburgh, Pennsylvania

Conditions: Depression, Amyotrophic Lateral Sclerosis
Interventions: Tricyclic Antidepressants ("TCA"), Selective Serotonin Uptake Inhibitors ("SSRI"); Drug
Lead sponsor: St. Louis University; Other
Eligibility: 25 Years to 80 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Obsessive Compulsive Disorder, Major Depressive Disorder, Anxiety
Interventions: Not listed
Lead sponsor: University of Florida; Other
Eligibility: 8 Years to 20 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Gainesville, Florida

Search by objective public record fields.

Treatment of Depressed Chronic Obstructive Pulmonary Disease Patients

Major Depressive Disorder Study In Adults

Depression-Diabetes Mechanisms: Urban African Americans

A Trial of Sertraline vs. CBT for End-stage Renal Disease Patients With Depression {ASCEND}

Predicting SSRI Efficacy in Veterans With PTSD

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients

Safety and Effectiveness of S-adenosyl-l-methionine (SAMe) for the Treatment of Major Depression

A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication

Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy

Efficacy of Exercise for Sexual Side Effects of Antidepressants

Combined Mirtazapine and SSRI Treatment of PTSD: A Placebo-Controlled Trial

Escitalopram in the Treatment of Dysthymic Disorder, Double Blind

Preventing Chronic Depression and PTSD in Stroke Patients Admitted to the Neuroscience Intensive Care Unit (NICU) and Their Family Caregivers

A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder

A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

Glutamate Probes in Adolescent Depression

A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats

Identifying and Treating Depression in the Orthopaedic Trauma Population

An Adaptive Treatment Strategy for Adolescent Depression-Continuation

A Study of LY2216684 in Major Depressive Disorder in Patients Taking Selective Serotonin Reuptake Inhibitors

Drug Therapy to Treat Minor Depression

SSRIs vs. TCAs for Depression in ALS Patients

Integrating Pharmacogenomic Testing Into a Child Psychiatry Clinic